Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Amantadine Hydrochloride
Amantadine · 1 trial · 1 indication
Safety and tolerability will be compared between active treatment and placebo groups.
| Arm | Type | Description |
|---|---|---|
| MR-301 | ACTIVE_COMPARATOR | On first day, patient will receive MR-301 at 100 mg intravenous infusion BID. On second day, the dose is elevated to 150 mg intravenous infusion BID. On third day, the dose is further elevated to 200 mg intravenous infusion BID and maintained up to Day 21 |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Amantadine Hydrochloride | DRUG | MR-301 is an I.V. formulation for the treatment of TBI. The active ingredient is amantadine hydrochloride (HCl). |
| Placebo | DRUG | The placebo for this study is 0.9% Sodium Chloride IV Solution. |
Inclusion Criteria: 1. Age: 18 to 75 years. 2. Patients with TBI confirmed by CT scan or MRI 3. Patient have sustained a trauma between 72 hours to 1 week 4. Patient with Abbreviated Injury Score (AIS) ≤ 2. 5. Patients must be admitted to an acute care setting no less than 2 days prior to randomiza...
Amantadine is being studied as a treatment for patients with severe Traumatic Brain Injury (TBI). It is currently in Phase 2 clinical development as an investigational small molecule therapy for this condition. The drug is being evaluated for safety in this patient population.
Amantadine is a small molecule being developed for Traumatic Brain Injury. The specific molecular target for this indication has not been disclosed. The drug is being studied for its potential effects in patients with severe TBI.
Amantadine is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker symbol YCBD. The company is conducting clinical trials to evaluate the drug for the treatment of severe Traumatic Brain Injury.
Amantadine is currently in Phase 2 clinical development for the treatment of severe Traumatic Brain Injury. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 2 trial is active but not recruiting participants.
Amantadine is being evaluated in a Phase 2 clinical trial with the identifier NCT06253923. This study is assessing the safety of Amantadine Hydrochloride intravenous solution in patients with severe Traumatic Brain Injury. The trial is randomized, double-blind, and placebo-controlled, with an enrollment of 45 participants in the United States.
Yes, Amantadine is the same as Amantadine Hydrochloride. The drug is referred to by both names, with Amantadine Hydrochloride being the full chemical name. In clinical trials, it is being studied as an intravenous solution for the treatment of severe Traumatic Brain Injury.